































The role of N-acetyl-L-methionine as a new stabilizer 










Albumin products are widely used in treating a variety of diseases, including improving circulating 
blood flow during hemorrhagic and traumatic shock, maintaining colloid osmotic pressure during 
hypoalbuminemia due to a decrease in the ability of the liver to synthesize albumin. As the only source 
of human serum albumin (HSA) for clinical application is from donated human blood, which involves 
a risk of transmitting pathogenic viral diseases, such as hepatitis, human immunodeficiency virus 
(HIV), and as yet unidentified diseases. HSA is pasteurized by heating at 60°C for several hours with 
sodium octanoate (Oct) and N-acetyl-L-tryptophan (N-AcTrp), commonly used stabilizers, a process 
that usually destroys the viruses present. We have previously shown that Oct has the greatest stabilizing 
effect against heat, while N-AcTrp diminishes the oxidation of HSA. However, N-AcTrp has a possible 
side effect of intracerebral disease. In order to provide a new, safer stabilizer for albumin products 
without the risk of side effects instead of N-AcTrp, we investigated the usefulness of 
N-acetyl-L-methionine (N-AcMet) in comparison with N-AcTrp for long-term stability, including 
photo-irradiation and the oxidation of albumin products. 
 
1) The effect of N-AcMet on the oxidation and thermal stability of HSA 
? The effect of N-AcMet on oxidation was examined using 2,2’-Azobis (2-amidino-propane) 
dihydrochloride (AAPH) as an oxidizing agent. The carbonyl content in the presence of N-AcMet and 
both Oct and N-AcMet were significantly decreased. The effect of AAPH on the oxidative status of 
Cys34 on HSA was also studied by HPLC. N-AcMet exerted a substantial protective effect on the 
sulfhydryl group. Further, N-AcMet was found to be a superior radical scavenger to N-AcTrp using 
1,1'-diphenyl-2-picrylhydrazyl (DPPH) radicals. The thermal stability of both Oct and N-AcMet was 
manifested as an increase in the denaturation temperature and calorimetric enthalpy, as determined by 
differential scanning calorimetry (DSC). Thus, N-AcMet can be considered to be sufficiently strong to 
act as a stabilizing agent having the same or more antioxidant activity with respect to HSA compared to 
the N-AcTrp. 
 
2) The validation of N-AcMet in comparison with N-AcTrp for photo-stability of HSA  
The protective effect of N-AcMet and N-AcTrp on the photo-irradiation of HSA was investigated. 
We first investigated the stabilizing effect of N-AcMet and N-AcTrp after the photo-irradiation by 
circular dichroism (CD) spectra and DSC. The stabilizing effect of Oct was also found to be superior to 
that of N-AcMet and N-AcTrp, as evidenced by the ?-helical content of HSA and thermal stability 
after photo-irradiation. In contrast to N-AcMet, N-AcTrp abolished the positive effect of Oct when the 
two compounds are used together. Thus, N-AcTrp is not able to protect the structure of HSA during 
photo-irradiation. Next, the hydroxyl radical (?OH) scavenging activity of HSA with additives after 
photo-irradiation was examined. N-AcMet was found to be superior to N-AcTrp in scavenging ?OH 
and in protecting HSA both against ?OH and prolonged exposure to light. The extent of oxidation of 
HSA after photo-irradiation was also evaluated by measuring the content of carbonyl groups in the 
molecule. The photo-irradiation of HSA in the presence of N-AcTrp resulted in an increased formation 
of carbonyl groups. By contrast, N-AcMet diminished the content of carbonyl groups. Thus, N-AcMet 
is superior to N-AcTrp, because exposure to light photo-degrades the latter to produce potentially toxic 
compounds which promotes the photo-oxidative damage of albumin. Therefore, compared to N-AcTrp, 
N-AcMet is a safe and risk-free stabilizer of albumin during photo-irradiation. 
 
3) Binding mode of N-AcMet and Oct on the HSA molecule 
The binding capacity of the N-AcMet, Oct was investigated using an ultrafiltration method. The 
binding constants of Oct and N-AcMet was found to be 1.3 x 106 M-1and 5.5 x 104 M-1, respectively. In 
addition, a HSA?N-AcMet?Oct ternary complex was prepared and subjected to X-ray crystallography. 
The overall structure of the HSA?N-AcMet?Oct complex is composed of a heart-shaped structure, the 
binding site of the N-AcMet appear to be subdomain IIA, otherwise major binding sites of Oct appear 
to be a subdomain IIIA. In detail, the carboxyl group of N-AcMet bound to subdomain IIA was 
presumed to form hydrogen bonding with the side chain of Lys195 and Arg222. Interestingly, this 
binding site was clearly different from N-AcTrp bound to the subdomain IIIA. These data suggest that 
N-AcMet effectively exerts antioxidant activity than N-AcTrp. 
 
4) The validation of N-AcMet in comparison with N-AcTrp for the oxidative modification of HSA 
? The protective effect of N-AcMet and N-AcTrp on the oxidative modification of HSA was 
investigated. Chloramine-T (CT) was used as a model compound for mimicking oxidative stress. The 
treatment of HSA with CT resulted in the formation of a pronounced number of advanced oxidation 
protein products (AOPP) and carbonyl groups. Oxidation in the presence of N-AcMet or N-AcTrp 
results in a decreased amount of AOPP and carbonyl groups. In particular, the protective effect of 
N-AcMet is pronounced, because the AOPP and carbonyl groups formed in its presence is lower than 
the amount formed in the presence of N-AcTrp and much lower than that formed in the absence of an 
additive. In addition, CT-HSA with N-AcMet is superior for scavenging peroxynitrite and ?OH 
compared to CT-HSA with N-AcTrp. Finally, in an attempt to evaluate whether the CT-induced 
oxidations without and with additives had any effect on the biological fate of HSA, plasma half-lives 
and the bio-distribution of the HSAs in mice was determined. CT-HSA with N-AcMet showed longer 
half-lives as compared with that of CT-HSA with N-AcTrp and non-additive CT-HSA. Furthermore, 
the liver uptake of CT-HSA with N-AcTrp were much more pronounced than that of CT-HSA with 
N-AcMet. These results reveal that N-AcMet has a superior protective effect on HSA against 
post-translational oxidation compared to N-AcTrp. 
 
? In conclusion, the above findings strongly suggest that N-AcMet functins as a stabilizing agent and 
that it is a more effective antioxidant of albumin products compared to N-AcTrp. The results obtained 
in this study may lead to basic data that can be useful for developing albumin products that are more 
efficacious and safer than the currently used products. 
???????????? 
 
AGE ?????? advanced glycation end products 
AOPP ????????? advanced oxidized protein products 
CD ???? circular dichroism 
CD36  cluster of differentiation 36 
CT ????? T chloramine T 
DNSS ????????? dansylsarcosine 
DPPH 1,1'-?????-2-????????? 1,1'-diphenyl-2-picrylhydrazyl 
DSC ?????????? differential scanning calorimetry 
ESR ??????? electron spin resonance 
HMA ?????????? human mercaptalbumin 
HNA-1 ??????????-1 human nonmercaptalbumin (disulfide) 
HNA-2 ??????????-2 human nonmercaptalbumin (oxidized) 
HSA ????????? human serum albumin 
ICG ??????????? indocyanine green 
MPD 2-???-2,4-???????? 2-methyl-2,4-pentanediol 
N-AcCys N-????-L-????? N-acetyl-L-cysteine 
N-AcMet N-????-L-????? N-acetyl-L-methionine 
N-AcTrp N-????-L-??????? N-acetyl-L-tryptophan 
Oct ?????????? sodium n-octanoate 
PDB ??????????? protein data bank 
r.m.s.d. ?????? root mean square deviation 
ROS ????? reactive oxygen species 
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Table 1.  Pharmaceutical component of albumin products 
  20 mL product 50 mL product 




Oct 54.0 mg (16.2 mM) 135 mg (16.2 mM) 





N-Formylkynurenine?Kynurenine ?? Quinolinic acid ???????????????????






????? (SSRI) ??????????????????????? (SNRI) ??????????
???????? Trp ???????????????????? 10)??????????????
























HSA ????? 600 μM ?????????????????? 60% ???????
HSA ?????????????????????????????????????????
???????????????????????????????????????????
??????????????????????????????????????? 12, 13)?HSA 
???????????????????????????????????? Superoxide 
dismutase (SOD)??????????????????????????????????????
???????????????????????????????? 14)??????HSA ? 34 ?
????????? (SH) ????????? (Cys) ?? (Cys34) ? 6 ??????? (Met) 
???????????????????????????????????????????Cys34 
?????????SH ??? 80% ???????????????????????????
???????? 15, 16)? ????????????HSA ?????????????????? 
(Cys34 ?Met ? 6 ??) ????????????????????????????Cys34 ?
???? (Ala) ????? C34A ???? Met 6 ????? Ala ??????????????
Cys34 ? Met 6 ????? Ala ????????????????????????????
Cys34 ?? Met ????????????????????????????????? (O2?-) 
????Cys34 ??????????HSA ????60% ????Met 6 ???30% ?????
???hydrogen peroxide (H2O2) ??????Cys34 ??70%?Met 6 ???60% ???????
??????????????????????????????????????????????
? (?OH)?????? (NO) ?????????????????????Cys34 ?????OH 








???? N-AcCys ????????N-AcTrp ?????????????? 5)?????????
????N-AcCys ??HSA ???Cys34 ???????????????????Cys34 ???
??????????????N-AcCys ????? Cys34 ???????????????????
????????????????????? 18-20)???????? SH ?????????????
????? Met ??????????????????Bourdon ?????Met ????????
???????????Met ???????? T ????????????? HSA ???????
??????HSA ??????????????????????????40~80% ?????
????????? 21)??????????????????????????????????
????????????????HSA ?????????? SH ???????????????
?Met ???????????????????????????? 22)??  
??????????????????????????????N-????-L-????? 
(N-AcMet) ?????????????? 2 ???????????????????????




X ???????????N-AcMet ?????????????????????????? 5
?????????????????????????????????????? N-AcMet ?




Fig. 3.  Chemical structure of N-acetyl-L-methionine (N-AcMet). 
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?????????????????????????????????? Oct ? N-AcTrp ??
?????Oct ????????????????N-AcTrp ? HSA ??????????????
????????????? 5)??????? Trp ????????????????????????
???????????????????????????????? 7-9)????????????
????????????????? N-AcTrp ????????????????????????
?????????????????????????????????HSA ???? Cys34 ?
????????????????????????????????????????????
???Met ???????????????????????? 17)?Stadtman ??????????
?????????Met ??????????????????????????????????
???? 23)?????????????????? N-AcCys ??HSA ???? Cys34 ?????










? ???HSA ???????? 2,2'-???? (2 ????????) ???? (AAPH) ????HSA 
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Fig. 4.  AAPH-induced oxidation of HSA alone (control) and in the 
presence of ligands.  




HSA ?????? 35 ?? Cys ???????????? 17 ? (34 ?) ??????????
???????3 ??????? 9 ????????????????????????????
?????Cys34 ??????????????????????????????? Cys34 ???

































Cys34 ?SH ???????????????????????????SH ????????????
?????????????????? 25-28)?????? HSA ?????Cys34 ?????????
????????????????HSA ????????????????4-VP-Me ?????
?????? 6)?Fig. 5 ???? 1 ??????????? (HMA)?? 2 ????????????
????????????????????????????? (HNA-1)?? 3 ???????????
???????????????????? (HNA-2) ????AAPH ??????? HSA ???
??????????????????????????? (Fig. 5A)?HSA ????????????
???????????Oct ?????????????????  (Fig. 5B)????????
N-AcMet ?????? N-AcMet ? Oct ???????  (Fig. 5C, D)??????????? 
(HMA) ?????????? (HNA-2) ????????? (Table 2)?  
 
 
Fig. 5.  HPLC chromotograms of HSA before (upper curves) and after AAPH-induced oxidation 
(lower curves).  
(A) Oxidation of albumin in absence of ligands, (B) Oxidation in the presence of Oct, (C) Oxidation in 
the presence of N-AcMet, (D) Oxidation in the presence of N-AcMet and Oct. Peaks correspond to 
HMA, HNA-1 and HNA-2. Data shown are from representative experiments. 
 
(C) (D)
0 3 6 9 12 15
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Retention time (min)
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Retention time (min)
0 3 6 9 12 15
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Table 2.  Relative fractions of HMA, HNA-1 and HNA-2 (%) before and after 
AAPH- induced oxidationa 
 
a The concentration of HSA was 50 μM, and that of AAPH and the ligands was 10 mM 
and 250 μM, respectively. The results are average values ± SD for three experiments. * P 
< 0.05 as compared with HSA alone. 
 
?-?? 1,1'-diphenyl-2-picrylhydrazyl (DPPH) ??????? 
 
N-AcMet ?? N-AcTrp ???????????????????????????????
???????DPPH ????????????????????? 29)??????N-AcMet ??
N-AcTrp ?????????????? DPPH ????????????? (Fig. 6)????
N-AcMet ??????????N-AcTrp ??????????????????????????
??????????????? Oct ???????????????????????????? 
(Data not shown)? 
  
Fig. 6.  DPPH radical scavenging activity of HSA with ligands. 
The values are means ± SD (n=4). * P < 0.05, compared with HSA only. ** P < 
0.05, compared with HSA + N-AcTrp. 
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39.3 ? 2.3 *
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???? HSA ???? N-AcMet ??????? 
 





????????????????????????????????N-AcMet ?? Oct ????
HSA ????????? DSC ????????????????????? 
? Fig. 7A ?? Fig. 7B ??Oct ???? N-AcMet ?????????? HSA ???????
????????? DSC ?????????????????????????????????
?? Table 3 ?????????? Oct ??????????? HSA ???????? (Tm) 
???????????????????????????????????????? (?Hcal) ?
???????N-AcMet ?????????????? Tm ??Hcal ????????????








Fig. 7.  Effect of Oct and N-AcMet on the thermogram of HSA obtained by DSC.  
(A) Curves for samples that were not preheated. (B) Curves for samples which have been preheated for 
30 min at 60°C. Results are shown for HSA alone (     ), HSA with N-AcMet (     ), HSA with Oct 
( ), and HSA with both ligands (-----). Data are averages of three experiments. 
 
Table 3.  Thermodynamic data obtained from DSC of different HSA samples at pH 7.4a 
 
a The concentration of HSA was 0.1 mM, and that of the ligands was 0.5 mM. The results are average 
values ± SD for three experiments.?  
b Preheating was incubation at 60˚C for 30 min.?  
c No normal thermogram could be detected. 
(A)
Temperature (˚C)














































10 40 50 60 70 80 90
HSA 59.50 ? 0.06 
TmProtein samples ΔHcal ΔHv /ΔHcal
(˚C) ( X 102 kcal/mol)
1.64 ? 0.11 0.7 ? 0.01 
HSA + Oct 66.83 ? 2.10 2.10 ? 0.15 0.7 ? 0.01
HSA + N-AcMet 60.06 ? 0.10 1.71 ? 0.05 0.7 ? 0.03




HSA + Oct 66.80 ? 0.04 2.10 ? 0.19 0.7 ? 0.01
HSA + N-AcMet 61.58 ? 0.06 0.91 ? 0.25 1.9 ? 0.01













???AAPH ??? HSA ???????? HSA ?????????????????N-AcMet 
?????????????????????????????? (Fig. 4)??????????
???????? HSA ??????????????????????????????????
????????? N-AcMet ??????????????? 30)???????????????
????????N-AcMet ???????????????????????????????
????? (Fig. 5)?????????Oct ? N-AcMet ???????????????????
?????Nalini ??????? HSA ???????????????????????????
????????????? 31)????????? AAPH ?????????????????
??????????????????? HSA ??????????????????????
Kousa ???Oct ???????????????????????????? III ?? Oct ???
??????HSA ? C ??????tighting???? HSA ???????????????????
?????????????????? Oct ??????????????????????? 32)?
????????????? HSA ?????????Oct ??????????????Oct ?
HSA ???????? III ??????????????N-AcMet ??????????????
???????????????????????????????N-AcMet ?? N-AcTrp ?
DPPH ????????????????????????N-AcMet ? N-AcTrp ???????
? DPPH ????????????? (Fig. 6)????????N-AcMet ??N-AcTrp ?????
HSA ????????????????????????????????????????? 
???N-AcMet ?? Oct ????? HSA ???????????? DSC ?????
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????????van 't Hoff ????????? (?Hv) ??Hcal ?? (?Hv /?Hcal) ??????
????????????????????????????????? 1 ??????????





??????Hv /?Hcal ??? 1?????????????????? (Table 3)????N-AcMet 
?? Oct ??????Hv /?Hcal ??? 1 ?????????????????HSA ?????
??????N-AcTrp ?? Oct ???????????????? 5)?  
?????????Trp ??????????????????????????????
????????????????????N-AcMet ????????????????????





?????N-AcMet ? HSA ?????????????????????????????
?????????? 
 
1)  AAPH ? HSA ??????????????????????????????????
?????????????????????Oct ? AAPH ? HSA ??????????????
????Oct ? N-AcMet ?????????????????????????Oct ???????




2)  N-AcMet ?? N-AcTrp ? DPPH ????????????????????N-AcMet ??
???????? N-AcTrp ?????????????????????? 
 
3)? N-AcMet ?? Oct ???? HSA ????????? DSC ????????????
N-AcMet ? Oct ???????? HSA ????????????? 
 































? N-AcTrp ???????????????????????????????? 
????????? EU ??????????? (International Conference on Harmonization 




Kynurenine ??? Kynurenine ???????????????? Reactive oxygen species (ROS)  
????????????????????????????????????HSA ??????
????????????? 38)????Trp ????????N-Formylkynurenine?Kynurenine ??
Quinolinic acid ???????????????????????????????????????
????????? 7, 8, 39)?????? N-AcTrp ???????????????????????
??????????????????????????????HSA ?????????????
???????????????????????????? 
???????????????????????????????????????? 120 ? 
lx?hr ??????????????????????????? HSA ????????????
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????????????????????????? N-AcMet ????? N-AcTrp ????
???? 
 
???? ??? HSA ?????? 
 
?-?? ???? (CD) ????? 
 
? ???????? HSA ?????????? CD ????????????????????
???????????????????????????????????? HSA ? CD ??
????????????????????????????? (Fig. 8A)???????????
Oct ? N-AcMet ?????? Oct ?????? CD ?????????????????????
?????????????? α-??????????? 14% ????????????????
?????? (Fig. 8B, Table 4)????N-AcTrp ???Oct ? N-AcTrp ???????????
?????? α-??????????????? 23.8%?21.5% ?????????? HSA ???
????????????????  
 
Fig. 8.  Effects of additives on the far-UV CD spectrum of HSA.  
(A) Before photo-irradiation. (B) After photo-irradiation for 4 weeks. Results are shown for HSA alone 
(  ), HSA + Oct (  ), HSA + N-AcMet (  ), HSA + N-AcTrp (  ), HSA + 
Oct + N-AcMet (  ) and HSA + Oct + N-AcTrp (  ). The concentration of HSA was 10 























































? ?????????????? HSA ???????????? DSC ????????? 
Fig. 9 ??????????? DSC ???????????????????????????
????? Table 5 ????Oct ?????HSA ?????????? (Tm) ????????
????Oct ?? N-AcMet ?????????????????Hcal ??Oct ????????
?????????????????? HSA ?????????????????Oct ??
N-AcTrp ???????Hcal ?Oct ??N-AcMet ????????????????????





Table 4.  Alpha helical content of different HSA preparations calculated from CD spectra before 



























56.2±2.4 64.8±2.0 56.3±1.9 51.6±1.9 67.4±1.6 56.7±1.8 
(A) - (B) (%) 22.3±1.2 14.2±1.3 23.9±2.3 23.8±2.1 14.2±1.1 21.5±2.2 
a The concentration of HSA was 10 μM and that of each additive was 50 μM. The results are means ± 





Fig. 9.  Effects of additives on the thermogram of HSA obtained by DSC after photo-irradiation 
for 4 weeks.  
Results are shown for HSA alone (  ), HSA + Oct (  ), HSA + N-AcMet (  ), 
HSA + Oct + N-AcMet (  ) and HSA + Oct + N-AcTrp (  ). The concentration of HSA 



























Table 5.  Thermodynamic data obtained from DSC of different HSA samples after 
photo-irradiationa 
Protein samples Tm (ºC) ?Hcal (kcal/mol) ?Hv/?Hcal 
HSA alone 59.1 ± 0.05 10.1 ± 1.0 6.0 ± 0.10 
HSA + Oct 64.3 ± 0.09 73.7 ± 1.5 0.2 ± 0.05 
HSA + N-AcMet 59.7 ± 0.07 13.6 ± 4.9 4.2 ± 0.08 
HSA + N-AcTrp NDb ND ND 
HSA + Oct + N-AcMet 65.0 ± 0.10 67.4 ± 1.2 0.8 ± 0.05 
HSA + Oct + N-AcTrp 65.0 ± 0.11 27.0 ± 1.1 2.2 ± 0.09 
a The concentration of HSA was 20 μM and that of each additive was 100 μM. The results are 
means ± SD (n = 3). 
b No normal thermogram could be detected.  
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???? ??? HSA ?????? 
 
?-?? ??????? (ESR) ???????? 
 
? ESR ??????????????????????????? ROS ??????????????
????????????????????? ESR ?????????????????????
???????????????OH ??????????? DMPO (5,5‘-dimethyl-1-pyrroline-N-oxide) 
??????ESR ?????????????OH????????????????????HSA ?
????N-AcMet ?N-AcTrp ??OH???????????????????????????
??????5 mM ? 10 mM ???? N-AcMet ? N-AcTrp ????????????????




??????????????????? (Fig. 11A)????????? DPPH ????????
??????????N-AcMet ???????????? (Fig. 6)?????????????
N-AcMet ?????????????????????????N-AcTrp ?????????
?????????????????????? (Fig. 11B)?????????????????





Fig. 10.  Relative hydroxyl radical scavenging activities of different concentrations of N-AcMet 
(  ) and N-AcTrp (  ).  
The left part shows representative spectra without and with N-AcMet. Each point in the right part 




Fig. 11.  Relative hydroxyl radical scavenging activity of HSA in the presence of different 
concentrations of Oct (  ), N-AcMet (  ), N-AcTrp (  ), Oct + N-AcMet (  ) and Oct + 
N-AcTrp (  ) before (A) and after (B) photo-irradiation for 4 weeks.  
The scavenging activity of HSA alone was 5.5 ± 1.1% before photo-irradiation but very small after 
photo-irradiation. The concentration of HSA was 20 μM. Each point represents the mean ± SD (n = 3). 












































































































? ??????????????????????????????????????? HSA ?
???????????????????N-AcTrp ????? N-AcTrp ? Oct ????????
HSA ????????????????????????????????? (Fig. 12A)????
N-AcMet ???????? Oct ?????????????????????????????
???????????Oct ???????????????????????? 
? ??????????????????????????????????? (DNPH) ?????
??SDS-PAGE ????????? DNP ?????? western blot ?????????????
??????????????????????????????? SDS-PAGE ???????
?????N-AcTrp ????? Oct ??????????????????N-AcTrp ?????
??????HSA ??????????????????? (Fig. 12B)????N-AcMet ???
?? Oct ???????????????????????HSA ??????????????
?????????? DNP ?????? western blot ???????????????????
??? HSA ??????????????????????????N-AcTrp ????????
???? HSA ?????????????N-AcMet ??????????????????






Fig. 12.  Evaluation of oxidation of HSA which had been photo-irradiated in the absence 
(control) or in the presence of additives.  
(A) Carbonyl contents of the HSA preparations. The protein concentration was 20 μM and that of each 
additive was 100 μM. (B) SDS-PAGE electrophoresis. The concentration of HSA was 20 μM and that 
of each additive was 100 μM. (C) Western blots and staining with Oxyblot Kit reagents. (D) Carbonyl 
formation of oxidized HSA was determined as densitometry ratio of DNP area and protein area. Each 
column in (A) and (D) represents the mean ± SD (n = 3–4). * P < 0.05, ** P < 0.01, compared with 



































































































































































??????????? N-AcMet ? N-AcTrp ???????????????????????
???????????????????????? N-AcMet ? N-AcTrp ???????????
?????????????????????????????????????? 4 ???
???????????????? HSA ??????????????????????????
??????????? N-AcMet ????? N-AcTrp ???????? 
????????????OH ? O2?- ????????????????????????????
?????????????????????????????????????????????
??????? 40)?ESR ????????????????????????? HSA ??OH ??
??????????????????N-AcTrp ?????OH ???????????????
???????? (Fig. 11B)???????????????N-AcMet ???????????
????????????????????????????????N-AcTrp ????? Oct ?
????????????????????????????N-AcMet ???????????
?????????????????????? (Fig. 12A)?????????????????
N-AcTrp ????????????????????????? HSA ?????????????
???????????????????????? N-AcMet ? N-AcTrp ??????????
???? (MS) ????????????Trp ????????????? Picolinic acid ???
?? ?  (Data not shown) ? ?? ? Picolinic acid ? ? ? ? ???????? ?? ?
N-Formylkynurenine?Kynurenine ??????????????Quinolinic acid ????????





????? ROS ??? HSA ???????????????????????????????
????????????????AAPH ????????????? (His)?Trp????? (Tyr)?
Met ?????????????????HSA ????????????????? 41)?N-AcTrp 
??AAPH ?????????????????HSA? ??????????? 5)???????
???????? HSA ???????????????????N-AcTrp ??? AAPH ???
???MS ????????????Picolinic acid ??????????????????????
??? AAPH ??????????????????????????????????????
N-AcMet ??AAPH ?????????????????????????????N-AcMet 
? N-AcTrp ?????????????????????????????? 
????HSA ??????????????????????? CD ??????? DSC ?
??????? (Fig. 8, Fig. 9)????????????????Oct ??N-AcMet ?????
???Oct ?? N-AcTrp ????????????????????????????????
?? Oct ?? N-AcMet ???????HSA ???????????????????????
???Oct ?? N-AcTrp ????????Oct ?? N-AcMet ???????????????
?????????????????????? Oct ??HSA ???????????????
?????????????????? 5)?Oct ????????HSA ????? IIIA ??????
???????????????????? Oct ???? HSA ????????????????
?????????? 32)??????HSA ??? C ????????????????????
??????????????????????????????????????N-AcTrp ??
?? Oct ???????? HSA ??????????????????????????? Trp 
??????? Picolinic acid ???????? HSA ?????????????Oct ? N-AcTrp 
?????????????????????????????????????????????












1) HSA ??????? CD ????????????????????? N-AcTrp? ?? Oct ?
????????? α-????????????????????N-AcMet ?? Oct ?????
? Oct ??????????????????????????? 
 
2) ???????HSA ????????? DSC ??????????N-AcTrp ???????
??N-AcMet ???? HSA ????????????????? 
 
3) ???????????? ESR ?????????????????????????????
N-AcMet ? N-AcTrp ?????????????????????? 
 
4) ???????HSA ??????????N-AcTrp ?????????????????
N-AcMet ?????????????????? 
 









? HSA ????????? I (???????????) ????? II (?????????????) ?
????? 2 ?????????????? 42-44)?X ?????????????????????
???? I ????? II ???????????? IIA (?????? 197-297) ? IIIA (??????
384-497) ????????????????? 45, 46)??????????????????????
???? Oct ? N-AcTrp ? HSA ?????????????Oct ? N-AcTrp ??HSA ????
??? II ????????????????????? 5)???????????????????
???????????? II ???????????????? 47-52)???????????????
HSA ??????? II ??????????????????????????????????
N-AcMet ?????????? N-AcTrp ????????????????????????
?????????Oct ? N-AcMet ? HSA ???????????? 2???????????
?????? HSA ????????????????????????????????????
????????????N-AcMet ? HSA ???????????????????????
?????????? N-AcMet ? Oct ????????????? HSA?N-AcMet?Oct ????
???????????HSA?N-AcMet?Oct ???? X ??????????????????









???? HSA ? N-AcMet ?? Oct ?????? 
 
?-?? HSA ???? N-AcMet ? Oct ????????? 
 
HSA ???? N-AcMet ???????????Fig. 13 ???Scatchard ???????????
???????????? HSA ???? N-AcMet ?????? 5.5 x 104 M-1 ??Oct?HSA ???




Fig. 13.  Scatchard plot of the binding of N-AcMet to HSA as determined by ultrafiltration.  
Each point represents the mean ± SD (n = 4). 
 
 
?-?? HSA ??????? N-AcMet ? Oct ???????? 
 
? ????????HSA ????? 2 ?????????????????????????????


















N-AcMet ?? Oct ????????????????Fig. 14 ?????????? I ?????
???????????? WF ??????N-AcMet ???? Oct ??WF ?????????
??????????????????? II???? DNSS ??????Oct ???? DNSS ??
???????????N-AcMet ??????????????Oct ???? II ????????
??????????????Oct ???? II ?????????????????????????
?? I??????????????????Oct ???????????? I??????????
????????????N-AcMet ?????? I?????????????WF (1.0 x 106 M-1)2) ?
N-AcMet (5.5 x 104 M-1) ????????????????????????????Oct ????
???????? II??N-AcMet ???????????? I?????????????????Oct 
? N-AcMet ???? HSA ????1 : 1 ??????????????????????????





Fig. 14.  Effects of displacer ligands on the fluorescence intensity of warfarin (A) and 
dansylsarcosine (B).  
The displacer drugs used in this experiment were N-AcMet (?), Oct (?). 
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???? HSA ? N-AcMet ?? Oct?????? X??????? 
 
? ? 2???????N-AcMet ?Oct ???????????????????????????HSA?





HSA?N-AcMet?Oct ?????????????N-AcMet ?? Oct ????????????
??????????????????????????? HSA ?????? 5 ???????
??????????????????????????????????????????
N-AcMet ?????? 5.5 x 104 M-1?Oct ?????? 1.3 x 106 M-1 ?????? 20?????












??Oct ????? 6?10??????????????????????Oct ? 6?9?????
30 
 
????Fig. 15 ????????????????Oct ? 10?????????????????
???????????Oct ? 9?????????????????? X???????????





Fig. 15.  HSA?N-AcMet?Oct crystals. 
The best co-crystals of the HSA?N-AcMet?Oct complex were obtained in 2 weeks at 288 K by the 















Table 6.  Data-collection and refinement statistics 
Values in parentheses are for the highest resolution shell 
Data-collection  
Source SPring-8 BL44XU 
wavelength ?Å? 0.9000 
Space group P21 
Unit-cell parameters 
  length (Å) 
  angle (?)  
 
a = 58.9, b = 181.4, c = 59.8, 
? = 104.6 
Resolution range ?Å? 50.0 – 2.60 (2.64 – 2.60) 
No. of observed reflections 140,636 
No. of unique reflections 37,447 
Multiplicity 3.8 (3.9) 
Completeness ??? 98.7 (100) 
Rmerge???a 7.0 (64.2) 
?I/? (I)? 32.3 (2.5) 
  
Refinement  
Resolution ?Å? 36.3 – 2.60 (2.67 – 2.60) 
Reflection used 36,735 (2,821) 




Completeness ??? 98.7 (99.6) 
Number of non-hydrogen atoms 8,088 
  Protein 
  Ligands 




r.m.s.d. from ideality  
  bond length ?Å?   
  bond angle ???   
0.001 
0.413 
Average. B-factor 101.1 
  Protein 
  Ligands 




Ramachandran plot   
  favored region ???      
  allowed region ???      





a Rmerge ? 100 × ?hkl ?i ?Ii(hkl) ? ?I(hkl)?? / ?hkl ?i Ii(hkl), where ?I(hkl)? is the mean value of I(hkl).  
b Rwork ? 100 × ?hkl ??Fo? ? ?Fc? ? / ?hkl ?Fo?, where Fo and Fc the observed and calculated structure 
factors, respectively. c Rfree is calculated as for Rwork, but for the test set comprising 5% reflections not 




?-?? HSA?N-AcMet?Oct ???????? 
 
? SPring-8 BL44XU ?? X ????????????????? HSA?N-AcMet?Oct ????
??????? P21 ????????? a=58.9 Å?b=181.4 Å?c=59.8 Å?? =104.6? ???????
??????????????? X ??????????????????????????HSA?
N-AcMet?Oct ????????? 2.6 Å ?????????????? (Fig. 16)????? X?
??????????????????? Table 6 ????????? HSA?N-AcMet?Oct ??
?????????????? 2 ??? HSA (?? A ??? B) ??????????????
HSA ?? A ??? B ?????????????????? 498 ??????? C? ????
r.m.s.d. ?? 0.54 Å ???????????????????????????? (Fig. 16B)? 
? HSA ??????????????????? HSA ????????????????????
?????-??????????????? 3?????? (I?II?III) ??????????????
????????????????A???????B??????? (Fig. 16A)?Curry ??????
??? (????10?18) ? HSA ?????????????????????????????
??????????HSA ????????????????????? 53, 54)?????Oct (??
??8) ??????????????? (????10) ????? HSA ??? (PDB code 1e7e54)) 
????????????? 476 ??????? C? ???? r.m.s.d. ?? 2.98Å ????????
HSA?N-AcMet?Oct ??????????????????????? HSA ?? (PDB code 
1ao655)) ????????????? 532 ??????? C? ???? r.m.s.d. ?? 0.70 Å ????
???????? HSA?N-AcMet?Oct ????????????????????? HSA ??
?????????????????????????Dali ????56)???? HSA?N-AcMet?Oct 
?????? HSA ??????????????????HSA ????????? (PDB code 
2vuf57)?r.m.s.d.?=0.85 Å?515 ??????)?HSA ???????????? (PDB code 2bxh58)?
r.m.s.d.?=0.89 Å?528 ??????) ??HSA ?????-L-???????? (PDB code 2xw159)?
33 
 
r.m.s.d.?=0.98 Å?534 ??????) ?????????????? HSA ??????????
???????? 
? N-AcMet ???????????? IIA ??????????? Sudlow ???????????
????????? I ??????? (Fig. 16A)43)????Oct ????????????? IIIA 
(Oct 1) ???????? IIA ? IIB (?????? 298-383) ?? (Oct 2) ? 2 ??????????
?? Curry ???????????? 7????????????????????? 3? 4 (??
???? IIIA) ????????? 6 (?????? IIA? IIB??) ??????? (Fig. 16A)53)??
????????????????????Oct 1 ? Oct 2 ?? 25 Å?Oct 1 ? N-AcMet ?? 20 Å?
Oct 2 ? N-AcMet ?? 15 Å ???? (Fig. 16A)???????????????MPD ?????
?? IA (?????? 5-107) ??????? IIA ? 2???????????????????????
??? IB (?????? 108-196) ??????? IIIB (?????? 498-582) ???????????




Fig. 16.  Structure of the HSA?N-AcMet?Oct complex. 
(A) Overall structure. The HSA is shown as cartoon representations, and the subdomain structures are 
colored in blue (IA), cyan (IB), pink (IIA), red (IIB), green (IIIA), and palegreen (IIIB). The ligand 



















?-?? HSA ???? N-AcMet ????? 
 
? N-AcMet ??????? IIA ????????N-AcMet ????????? Lys195 ? Arg222




?????????? MPD ????????????????????????N-AcMet ?????
??????????????????MPD ?????????N-AcMet ? MPD ???????
??????????????????N-AcMet ???????????????????????
???????????????????????? HSA ?????????? I ????????
?????????????????? I???????????????????????????











Fig. 17.  N-AcMet binding site. 
(A) Close-up view of the N-AcMet binding site. The N-AcMet and MPD molecules are shown as 
ball-and-stick representations. Hydrogen bonds are shown as orange dashed lines. (B) The schematic 
diagram of the N-AcMet binding site. The amino acid residues involved in hydrogen bonds are 




?-?? HSA ???? Oct ????? 
 
  Oct ????????????? IIIA ???????? IIA ? IIB ??? 2 ????????? 
(Fig. 18A)?????????? IIIA ???Leu387?Ile388?Asn391?Cys392?Phe403?Leu407?
Arg410?Tyr411?Leu430?Gly431?Val433?Cys437?Cys438?Ala449??? Leu453 ???????
????????Oct ???????????????????????????????????
?????????????????????? (Fig. 18A, B)?????Oct ?????????
?? Arg410 ? Tyr411?Ser489 ???????????????????????? IIIA ????
HSA ?Oct ??????????????????????HSA ??A ????B ????
?????????????????? IIIA ?? Oct ??????????????? (PDB code 





























????? (Fig. 18C)????????????? 3 ? 4? Sudlow ??????????????
? II ????????????????Oct ????????????? II ??????????
??????????????? (PDB code 2bxf58)) ????????????????????
??????????????? (Fig. 18D)?????????????? IIIA ???? Oct ???
??????????? II ???????????????????????? 
? ?????????? IIA ? IIB ?????Arg209?Lys212?Ala213?Val216?Asp324?Val325?
Leu327?Gly328?Leu331?Leu347?Ala350?Lys351 ?????????????????????
?????????????? Oct ??????????????????????????????
????? (Fig. 19)???????????? IIA ? IIB ??????? Oct ??????????
??????? HSA?? A ???????????????????????? HSA ?? A ?






Fig. 18.  Oct binding site in the subdomain IIIA. 
(A) Close-up view of the Oct binding site in the subdomain IIIA. The Oct molecule is shown as a 
ball-and-stick representation. Hydrogen bonds are shown as orange dashed lines. (B) The schematic 
diagram of the Oct binding site in the subdomain IIIA. The amino acid residues involved in hydrogen 
bonds are surrounded by red boxes. (C, D) Comparisons of the binding sites of Oct, decanoic acid, and 
diazepam. The subdomain IIIA structures of the HSA?decanoic acid complex (PDB code 1e7e54)) and 
the HSA?diazepam complex (PDB code 2bxf58)) are superimposed on the HSA?N-AcMet?Oct 
complex. The structures of the HSA?N-AcMet?Oct complex, the HSA?decanoic acid complex, and the 
HSA?diazepam complex are shown as ribbon representations colored green, orange, and yellow, 
respectively. The Oct, decanoic acid, and diazepam molecules are shown as ball-and-stick 
representations, and their carbon atoms are colored white, gray, and cyan, respectively. Fatty acid 














































Fig. 19.  Oct binding site between the subdomain IIA and IIB. 
Close-up view of the Oct binding site between the subdomain IIA and IIB. The Oct molecule is shown 






? HSA ?????????? N-AcMet ? Oct ???????????????????????
???????? N-AcMet ? Oct ????????????????????2 ????????
???????????????? X ??????????? HSA?N-AcMet?Oct ??????
?????????????N-AcMet ?????? Oct ???????1/20 ????????? 2
???????????N-AcMet ?Oct ?HSA ???????????????????????
?????N-AcMet???????????? IIA??Oct???????????? IIIA?????
??? IIA ? IIB??? 2??????????????????????????????????
N-AcTrp????Oct?????????? IIIA ????????????????????????























? HSA ?????????????????????? ROS ???????????? N-AcMet
??????????????? I ???????????????????? HSA ??????
????????????????????????????? 







???????????????????????????? HSA ??????????? Oct
????????????????????????????????? HSA ? Oct ??????
????Arg410 ? Tyr411 ???????? HSA ?? Oct ?????????????????
???? 60)???????Oct ? HSA ???????????????????????????
??????????????????????1???Oct ??????? IIIA ????????
????????????HSA ???????????????????????????????
???????? IIIA ?? Oct ???????????????????????? 3? 4???
?????????????????????? HSA?N-AcMet?Oct ????????Oct ???
???????????????? 1??????????? 
? HSA ??????????????????????????????????Flora ?? HSA
? Cys34 ???????????????? HSA ? Trp214 ?????????????????
??????HSA ????? I ? II ??????????????????????????? 61)?
?????HSA ? 50?C??????????? I ????? II ????????70?C ???????
40 
 
II ?????????70?C ??????? I ???????????????????????
Galantini ???????????????? HSA ????????????? X ??????
????????????? 62)????????????????????????? HSA ????
??? III →???? II →???? I ??????????????????????????????
HSA ??????? III ????????????? IIIB ???????????????? IIIA ??
?????? I ? II ?????????????????? I ????? II ?????????????
???????????? IIIA ????? II ??????????????????????????
?????????HSA ?????????????? IIIA ??????????????? I ????
? II ??????????? II ???????? I ???????????????????????
??????????????????????????????????????????
?????????????????????????????????????????????
?????HSA ??????? IIIA ?????????????????? Fig. 20 ???????
?????????????????????? II ????????????????Oct ????
?????????????????????????????????????? II ??????
???????? IIIA ??????????????????????????????????
HSA ?????????????? 1 ???????????????? II ?????Oct ????










Fig. 20.  Intra-cavities of the subdomain IIIA. 
This figure is drawn with the HSA free-form coordinate (PDB code 1ao6). The subdomain IIIA 
structure is shown as a transparent green cartoon representation. The intra-cavities of the subdomain 
IIIA are shown as transparent yellow surface representations. The Oct molecule is shown as a CPK 
representation and is modeled by superimposing the subdomain IIIA structure of the HSA?N-AcMet?









?????HSA ?????????? N-AcMet ? Oct ?????????????????
?????????????? N-AcMet ??????????????????????????
???????????? X ??????????? HSA?N-AcMet?Oct ??????????
??????????????????? 
 
1) ??????????Oct ? N-AcTrp ? HSA ???????????????Scatchard ?






2) ?????????? N-AcMet ?? Oct ???????????????N-AcMet ???? I
?? (?????? IIA) ??Oct ???? II ?? (?????? IIIA)? ????????????? 
 
3) HSA?N-AcMet?Oct ?????????????N-AcMet ?? Oct ???????????
??HSA ????????? N-AcMet ? 10???Oct ? 8????????????????
????? 
 





5) ?????? IIIA ???? Oct ?????????????? II ?????????????
??????????? 
 
6) N-AcMet ? N-AcTrp ???????????????????? 1?????N-AcMet ? Oct
???????????????????? 
 















? ??????????N-AcMet ?????????? N-AcTrp ??????????????
????????????????????????????????????????????
?????????????????????????????????????????????
??????????????????? (ONOO-)??OH?????? (HOCl) ????????
??????????????????????????????????? 63-65)????????
??????????? HOCl ???????????????? HSA ??????? AOPP 




??HSA ???????????????????????????? HSA ?????????
??????????  
? ????????????????????????????????????? T ????









???? ??????? HSA ????? 
 
?-?? ????? T ?????????? HSA ??? 
 
?????????????????????????????????? HOCl ??????
???????????????T ????300 μM HSA ??????T 5 mM ?????1 ????
???????????????????????? HSA (CT-HSA) ???????CT-HSA ???
?????????????????????????????AOPP ?????????????
?????? CT-HSA ?????? T ????????? HSA (?? control) ????????
AOPP ??????????? (Fig. 21)?????????CT-HSA ?AOPP ???? 60 μM ??
??????????? AOPP ?? 50 - 200 μM66) ????????????????????
???????????????????????????? N-AcMet ????????????




Fig. 21.  AOPP content of non-treated HSA (control) and HSA treated with chloramine T.  
The concentration of HSA was 100 μM. Each point represents the mean ± SD (n = 4). ** P < 0.01, 
compared with control. ## P < 0.01, compared with CT-HSA additive (-). †† P < 0.01, compared with 


































?????????????? CT-HSA ?????????????????????? N-AcMet 
??????????????????????????????????????N-AcMet ??
??????????????? N-AcTrp ????????????? (Fig. 22)? 
 
 
Fig. 22.  Carbonyl contents of non-treated HSA (control) and oxidized HSAs. 
The concentration of HSA was 0.2 mM and that of each additive was 1 mM. Each point represents the 
mean ± SD (n = 3). ** P < 0.01, compared with control. ## P < 0.01, compared with CT-HSA additive 
(-). †† P < 0.01, compared with CT-HSA + N-AcTrp. 
 
????DNP ??????western blot ?????control ?????????????????
???????N-AcMet ???????????? CT-HSA ? N-AcTrp ???????????? 
HSA ???????????????  (Fig. 23A, B)?????N-AcTrp ????????


















































Fig. 23.  Evaluation of oxidation of non-treated HSA (control) and oxidized HSAs. 
(A) Western blots and staining with Oxyblot Kit reagents. (B) Carbonyl formation of oxidized HSA 
were determined as densitometry ratio of DNP area and protein area. Each point represents the mean ± 
SD (n = 3). ## P < 0.01, compared with CT-HSA additive (-). †† P < 0.01, compared with CT-HSA + 
N-AcTrp. 
 
?-?? ??????????? (ONOO-) ??????????????? (?OH) ??? 
 
???CT-HSA ? ONOO- ?????????????????? 123 ????????? ONOO-
???????????????????????????CT-HSA ? ONOO- ??????????
????????????????????????? CT-HSA ? ONOO- ???? control ?
??????????????? N-AcMet ???????????? CT-HSA ????????
ONOO- ???????????N-AcTrp ???????????????? (Fig. 24A)? 
???????????????????OH ??????????? DMPO ??????ESR ???
????????????CT-HSA ??OH ??????????????????????N-AcMet 
???????????? CT-HSA ???????????????????????N-AcTrp ?
???????????ONOO- ?????????????? (Fig. 24B)????????????









































Fig. 24.  Relative peroxynitrite scavenging activity (A) and hydroxyl radical scavenging activity 
(B) of non-treated HSA (control) and oxidized HSAs.  
(A) The concentration of HSA was 25 μM. (B)? The concentration of HSA was 50 μM.  
Each point represents the mean ± SD (n = 3). ** P < 0.01, compared with control. ## P < 0.01, compared 



























































































? SDS-PAGE ????????? HSA ?????????????????????? CT-HSA 
? N-AcTrp ???? CT-HSA ?????????????????????????????? 








?? DSC ????????????? CT-HSA ???????????????????
N-AcTrp ??????????? CT-HSA ?????????????????N-AcMet ???
??????????????????????? (Fig. 26)? ???DSC ???????????











????????? N-AcTrp ?????Hv ??Hcal ????1 ???????????????
????? 
? ??????????????N-AcTrp ???????? N-AcMet ???? HSA ?????
?????????? 
 
Fig. 26.  Thermogram of non-treated HSA (control) and oxidized HSAs obtained by DSC. 
(1) control, (2) CT-HSA additive (-), (3) CT-HSA + N-AcMet, (4) CT-HSA + N-AcTrp dissolved in 
































Table 7.? ? Thermodynamic data obtained from DSC of different HSA samples after CT 
induced oxidationa 
Protein samples Tm (ºC) ΔHcal (kcal/mol) ΔHv/ΔHcal 
control 60.8 ± 0.09 126 ± 3.0 0.66 ± 0.20 
CT-HSA additives (-) 61.7 ± 0.07 56.9 ± 2.5 1.18 ± 0.10 
CT-HSA + N-AcMet 61.2 ± 0.05 64.1 ± 2.9 0.70 ± 0.18 
CT-HSA + N-AcTrp 62.3 ± 0.10 57.4 ± 1.9 1.06 ± 2.9 
The concentration of HSA was 20 μM and that of each additive was 100 μM. The results are means ± 
SD (n = 3). 
50 
 
?-?? CD ????? 
 
???????????????????????HSA ????????????????
CD ????????????????????? T ?????? N-AcMet ?????? α-????
????????????????????? (Fig. 27, Table 8)??? N-AcTrp ????????
???????????????????????????? T ?????????????????
???????????????????N-AcMet ?????? T ?????????HSA ????
????????????????????? 
 
Fig. 27.  Far-UV CD spectra of non-treated HSA (control) and oxidized HSAs. 
(1) control, (2) CT-HSA additive (-), (3) CT-HSA + N-AcMet, (4) CT-HSA + N-AcTrp dissolved in 


































Table 8.  Alpha helical content of  non-treated HSA (control) and 
oxidized HSAs calculated from CD spectraa 
Protein samples Alpha helical content (%) 
control 80.7 ± 1.18 
CT-HSA additives (-) 61.7 ± 2.90 
CT-HSA + N-AcMet 72.6 ± 3.21 
CT-HSA + N-AcTrp 62.4 ± 2.35 





HSA ??????? Trp214 ????????????????????????? 280 nm ?
???????????????????????????????? 340 nm ????????
? (??????????)?????? (?? 295 nm ????????) ??????????
??????????????????????? Trp ??????????????? Trp ???
????????? 69-71)??????Fig. 28 ???????????? T ????????????
?????????????N-AcMet ??????????????N-AcTrp ????????





Fig. 28.  Intrinsic fluorescence spectra of non-treated HSA (control) and oxidized HSAs.  
(1) control, (2) CT-HSA additive (-), (3) CT-HSA + N-AcMet, (4) CT-HSA + N-AcTrp dissolved in 




































???? ??????? HSA ??????? 
 
?-?? Indocyanine green (ICG) ????????? HSA ??????????????? 
 
?????????? CT-HSA ?????????????????????????????
???? CT-HSA ? ICG ?????????????????????????????????
?????????? CT-HSA ? control ?????????????????????? (Fig. 
29, Table 9)????N-AcMet ?? N-AcTrp ???????????????????????





Fig. 29.  Relative plasma concentrations of ICG-labeled HSAs (control (●), CT-HSA additive 
(  ), CT-HSA + N-AcMet (  ), CT-HSA + N-AcTrp (  )) after intravenous administration 
in mice. 
The bars represent SD (n = 3-4). 
 
 
























?? Fig. 30 ???? 2 ?????????????????????????????????
?????????????? CT-HSA ?????????????????control ?????
??????????????????N-AcMet ??????N-AcTrp ???????????
????????????????????????????? N-AcMet ??in vivo ????? 
N-AcTrp ??? HSA ???????????????????????????? 
 
Fig. 30.  In vivo fluorescence imaging of control and oxidized HSAs labeled with ICG.  













Table 9.  Half-life of ICG-labeled HSAs 
Protein samples Half-life (hr) 
control 9.65 ± 0.46 
CT-HSA additives (-) 2.86 ± 0.40 
CT-HSA + N-AcMet 5.87 ± 0.20 **, ##, †† 
CT-HSA + N-AcTrp 4.98 ± 0.27 **, ## 
The data are average values of three or four experiments ( ± SD). ** P < 0.01, compared 
with control. ## P < 0.01, compared with CT-HSA additive (-). †† P < 0.01, compared with 






??? N-AcMet ?????????N-AcTrp ???????????????????????
????HOCl ????????????????????????????????????????
?????????????????????????? HOCl ??????????
methylguanidine (MG) ?????????????? 72)???MG-???????????HOCl ??
?????????????????????????????????????? 73)??????
????? HOCl ????????????????????????? 1???????????
????????????????? T ?????CT-HSA ??????????????????
????? T ??HSA ? Trp?Met?Tyr?????? (Arg)???? (Lys) ????????????
???? 74)??????????????? T ?????????????????????????




(Cardiovascular Disease : CVD) ??????????????????????? CVD ???
????????AOPP ?????????????????????????Witko-Sarsat ???
??????????????AOPP ??????????????in vitro ?????AOPP ??
????????????????????????????????? 75, 76)?????????
?????AOPP ???? TNF-α ?????????????????????????????
???? 66, 67)???AOPP ??????????????????????????????????





???????N-AcMet ???? CT-HSA ??N-AcTrp ???????? ONOO- ??????OH 
????????????????? (Fig. 24A, B)?????????N-AcMet ????????
?? N-AcTrp ?????????????????????????????????????
??? 
???N-AcMet ??????????????????DSC ????????? T ?????
?????????????????????????? N-AcMet ???? CT-HSA ?????
???????Hcal ??????? (Fig. 26, Table 7)??????????? N-AcTrp ????
CT-HSA ??Hv ??Hcal ??? 1 ????????????????????control ? N-AcMet 
??????Hv ??Hcal ??? 1 ??????HSA ????????????????????
????????????????????????????????????????????
??????HSA ???????????????? CD ?????????????????
????????????????????????????N-AcMet ?????????? HSA 
???????????????????????????????? (Fig. 27, Fig. 28)? 
? ICG ???? CT-HSA ????????????????????????????????
???????????????????????????????????????? (Fig. 29, 
Fig. 30, Table 9)??????????????? HSA ?????????????????????
??????????????Iwao ???CT-HSA ? α-????????????????????
???in vivo ???????????????????? 77)?????CT-HSA ????????
???????Trp?Arg?Tyr?Lys?Met ???????????????????????????
????????????????? CT-HSA ? α-?????????(CT-HSA additive(-) (61.7 ± 
2.9%) < CT-HSA + N-AcTrp (62.4 ± 2.35%) < CT-HSA + N-AcMet (72.6 ± 3.21%) < control (80.7 ± 
1.18%) ???????????????????????????????????? α-?????
????????????????? (r=0.874, p<0.01)????????????????????




???????????????????? 78, 79)??????????? CT-HSA ???????
??????????????????????????????????????????????
????????????????????????????????? LDL ?????????
SR-A (scavenger receptor class A)80, 81)??? LDL ? AGE ????????? CD36 ? SR-B1 
(scavenger receptor class B)82, 83)????????????????? LDL ?????????
SREC (scavenger receptor class F)84)?AGE ????????? FEEL-1 ?? FEEL-285, 86)????




???? 89-91)????AOPP ????????????????????????? (HK-2 ??) ??
??????????????????? CD34 ???????????????????????
???????????????????????????? TGF-β ?????????????
















?????HOCl ????????????????????? T ???? HSA ???????
?????N-AcMet ?? N-AcTrp ???????????? HSA ????????????
??????????????????????? 
 




2) ????? T ??? HSA ?????N-AcMet ????? N-AcTrp ????????????
????????????????? 
 
3) CT-HSA ????????????????? DSC ??????????N-AcTrp ????
?????N-AcMet ???? HSA ??????????????????? 
 
4) CT-HSA ???????? in vivo ????????????????N-AcMet ???????












??????????????? Oct ? N-AcTrp ??????????Oct ?????????
???????N-AcTrp ? HSA ?????????????????????????? Trp ??
?????????????????????????????????????????????
???????????????????????????????????? N-AcMet ?????
???????????????????? N-AcTrp ???????? 
??? 2 ????N-AcMet ??????????????????????????????
?????? 3 ????N-AcMet ???????????? N-AcTrp ??????????? 4
????N-AcMet ??????????????HSA ??????? N-AcMet ? Oct ????
?????????????????????? 5 ??????????????????????




??? ??????????????? N-AcMet ??????? ????? 
 
AAPH ? HSA ???????????????????????????????????
?????????????????Oct ? AAPH ? HSA ??????????????????
Oct ? N-AcMet ?????????????????N-AcMet ?? N-AcTrp ? DPPH ????
????????????????N-AcMet ?????????? N-AcTrp ??????????
????????????N-AcMet ?? Oct ???? HSA ????????? DSC ????
????????N-AcMet ???????????????????? HSA ?????????
???????????????????Oct ?N-AcMet ????????HSA ???????





??? ???????????????? N-AcMet ? N-AcTrp ??????? ????? 
 
HSA ??????? CD ????????????????????? N-AcTrp ??????
?? α-????????????????????N-AcMet ????? Oct ?????????
??????????????????HSA ????????? DSC ??????????
N-AcTrp ?????????N-AcMet ???? HSA ???????????????????
?????????? ESR ?????????????????????????????
N-AcMet ????? N-AcTrp ?????????????????????????????
??????HSA ??????????N-AcTrp ?????????????????N-AcMet 
?????????????????????????????????N-AcTrp ??????
?? HSA ?????????????Oct ? N-AcTrp ??????????????????
??????????????????????N-AcMet ? N-AcTrp ????HSA ??????
???????????????????????? 
 
3?? HSA ??????? N-AcMet ? Oct ?????? ????? 
 
HSA ?????????? N-AcMet ? Oct ?????????????????????
HSA ???? N-AcMet ???????????????????????????? HSA ??
??????????????? HSA?N-AcMet?Oct ??????????? X ???????
????????????????????Oct ? N-AcTrp ? HSA ?????????????
?????Oct ?????? 1.3 X 106 M−1?N-AcMet ??5.5 X 104 M−1 ????Oct ? N-AcMet 
????????? 20 ???????????????????????????????????




?????? IIA ???????????????Oct ???????????? IIIA ???????
IIA ? IIB ??? 2?????????????????????? IIIA ?????????????
????? IIA ????? N-AcMet ??????????Lys195 ? Arg222 ?????????
????N-AcMet ???????????? Lys199 ??????????????????
Trp214?Ala215?Arg218?Leu219 ??????????????????????????????
? IIIA ????? Oct ??????????Arg410 ? Tyr411?Ser489 ???????????
?????????????????????????? II ???????????????????
???????????????????? IIA ? IIB ??????????? Oct ????????
??????????????????????????????????????????????
???????????????????????????N-AcMet ? N-AcTrp ????????
??????????????????N-AcMet ? N-AcTrp ?????????????????
??? 
 
4?? ???????????????? N-AcMet ? N-AcTrp ??????? ????? 
 
HOCl ????????????????????? T ???? HSA ????????????
???? HSA (CT-HSA) ?????N-AcMet ?? N-AcTrp ???????????? HSA ?
???????????????????CT-HSA ???????????????????
AOPP ?????????????????????????????????????????
??????N-AcMet ? N-AcTrp ???????????????N-AcMet ?????? AOPP 
??????????????????????????N-AcMet ????CT-HSA ??N-AcTrp 
???????? ONOO- ??????OH ????????????? DSC?CD ????????




?????ICG ???? CT-HSA ????????????????????????????
???????N-AcMet ??????? N-AcTrp ??????????????????????
????? CT-HSA ?????????????????????control ??????????
????????????? N-AcMet ??????N-AcTrp ????????????????
??????????????????????????N-AcMet ? N-AcTrp ?????????








?????????????????? HSA ???????HSA ????????????????

















HSA (??????) ?????????????????? Chen ??? 93)????????
?? (??) ??????????????????????????????? 66,500 ????
N-AcTrp?????? T???????????????N-AcMet?Oct ? BP Biomedicals (Solon, OH, 
USA) ???????[Methyl-3H]-N-AcMet ?Moravek Biochemicals (Brea, CA, USA) ???????






????????????????????????? 2 ??????? Student ? t-???
??????????? 0.05?????????????????????????3??????






50 μM HSA (?????? 250 μM) ? 10 mM AAPH ? 67 mM ?????? (pH 7.4) ???




?.? ???????? ?HPLC ??? 
HPLC ????????????????? LC-4A ??? SPD-2ASUV ???????
C-R2AX ????????????????????????????????????(A) 0.05M 
???-??? (pH7,0) ???(B) 0.5M ??????????0.05M ???-????? (pH7,0) ??
30 ?????????????????? 0.5mL/min ???? 26)??????? UV ?? 280 
nm ???????????????????? 
 
?.? DPPH ?????? 
DPPH ???????? Sassa ??????????? 95)?DPPH ????0.25 mM DPPH ?
? (in EtOH) ? 50 mM 2-(N-morpholino) ethanesulfonic acid buffer (pH 5.5) ??????????
??DPPH ????HSA ????????????? 50 μM?250 μM ??????????25?C?
20???????????????????????? 540 nm ????????????? 
 
?.? DSC 
DSC ??MicroCal ??MC-2 ????????????????? 
????????????? 
 
???? ?1 K/min 
??????? ?100 μM 
????? ?500 μM 














HSA ??? 100 μM????????? 500 μM ????? 67 mM ?????? (pH 7.4) ? 4 
mL ????????????????????????????????? (PTH-400NC-D) 




JascoJ-720 ????????????????? CD ???????HSA ??? 10 μM (67 
mM ?????? pH 7.4) ?????1 mm ???????????????????????? 
 
???? : 250?200 nm 
Sensitivity : 500 mdeg 
Scan speed : 5 nm/min 
Time constant : 8 sec 
Step resolution : 0.5 nm 
Accumulation : 1 
 
????????? (Mean residue ellipticity : [θ]) ??? (1) ???????? 
cl10
][ ?? ?  (1) 
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????θ ??????? l  ???? (cm)?c ??????????????? (2) ?????? 
nCpc ?         (2) 
????n  ???????Cp  ????????? 
 
?.? DSC 
DSC ??TA Instruments ?? Nano-DSC ?????????? 
????????????? 
 
???? ?1 K/min 
??????? ?20 μM 








?.? ????????????? ?ESR ????????? 
???? (?) ? X-Band ????????? JES-FA100 ESR spectrometer ?????ESR ?
??????????????????????? 
 
Microwave frequency  : 9416.9 MHz 
Microwave power  : 8.0 mT 
Field modulation   : 0.1 mT at 100 kHz 
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Sweep time      : 2 min 
Amplitude    : 800 
Time constant   : 0.03 sec 
 
????????????? DMPO ???????????????????????4 mM ??




???? HSA ?????????????? 2????? Climent ?????? Himmelfarb 
???????????? 96)?67 mM ???????????? HSA ???? 5 mg/mL ???
??????????????? OxyBlot Kit ???? DNPH ???????15 μL? SDS-PAGE 
???? 12 mA 150??????PVDF ?? 60V 60??????? DNP ?????? western 
blot ?????????????????????????????? PBS ????? CBB ???






????? Ultrafree-CL ???????????? (30,000NMWL? Millipore ?) ?????
????HSA ???? 20 μM ???[3H] N-AcMet ???????????????????cold 
N-AcMet ??? 1~100 μM ?????????? 400 μL ?????????4000rpm?25?C? 20 




? (Cu)?????? 1 ????????????????(r)?????? 1 ??????????
?????????? (n)?????? (Ka) ?? (3) ?? Scatchard ???????????? 
r
Cu
 = nKa - Kar              (3) 
 
??? ??????? 
HSA???? 2 μM ????? 67 mM ?????? (pH 7.4) ? 2 mL?????????? 2 
?20μM ??????????? (WF?DNSS) ? 25?C ?????????????????????
???????? HITACHI ? F-2500 ??????????????????????????
????????????? 5?20 nm ????????????????????????????
????????? 
 
???? ?WF (320 nm)?DNSS (350 nm) 




??? (4) ??????????? 
p ?%??=?F1-F2
F1
?×?100?????????    (4) 
??? F1 ?? F2 ???????????????????????????? 
 
??? ???? HSA??????HSA?N-AcMet?Oct???????? 
? HSA?N-AcMet?Oct ?????????????? 58)????????? 
? ????????HSA ????-80?C??????????HSA ?????????????
?????? (50 mM ?????????? pH7.0?150 mM KCl) ?? 20 mg/mL ????????
???????2??? HSA ????????Hiload 16/60 Superdex 75pg ????????????
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???? HSA ??Vivaspin 15 (??????10,000) ? 50 mM ?????????? pH7.0 ???
??????????????????????????? HSA ????? 200 mg/mL ????
?????????? HSA ?????????????-80?C?????? 
? HSA?N-AcMet?Oct ??????????????????????????????????
??????Table 10 ???????????? HSA?N-AcMet?Oct ?????????? 1 ?
???????????????????????????????????????????????
???????????????????????? HSA?N-AcMet?Oct ?????????
Table 6 ??????????????????? 3?????????????????????
?????? 2?????????????? 
 
Table 10.  Crystallization conditions of the HSA?N-AcMet?Oct complex 
Condition (initial)  
Droplet : Total 2.0 ?L 




Reservoir : Total 0.5 mL 
 24%(w/v) PEG3350 
50 mM K phosphate buffer pH7.0 
 
Temperature :  4?C 
#1 contained 2.0 mM HSA, 10.0 mM N-AcMet, 10.0 mM Oct, and 50 mM K phosphate buffer pH7.0. 
 
Condition (after optimization)  
Droplet : Total 3.0 ?L 




Reservoir : Total 0.4 mL 
 28%(w/v) PEG3350 
10%(v/v) MPD 
50 mM K phosphate buffer pH7.0 
 
Temperature :  15?C 





? ???? HSA?N-AcMet?Oct ??????????????????????????????
??????????????????????????????????????PF (BL-1A?
BL-17A?NW12A) ? SPring-8 (BL44XU) ?????Table 11 ????????????????
??? X ??????????????? X ????????????????????
HKL200097)????? 
? ??????????????????????HSA????? (PDB code 2vuf57)) ?????
??????????????????????? CCP498) ??????? Molrep99) ??????
????????????????? PHENIX100) ??????? phenix.refine101) ???????
TLS (Translation Libration Screw-rotation) ?????????????????? PHENIX ???
???? phenix.find_tls_groups ???????????????????????? COOT102) ?
?????????????????????? MolProbity103) ????????????????
?????? PyMOL104) ?????? 
 
 










X-ray wavelength?Å? 1.1000 0.9800 1.0000 0.9000 


















?.? ????? T ?????????? HSA ??? 
???? 300 μM HSA ? N-AcTrp ?? N-AcMet ????????? 3??????5 mM ?
????? T ? 67 mM ?????? (pH 7.4) ?????????37?C?1???????????3




? ? 2????? Climent ????????????????????? 
 
?.? ????????? (AOPP) ??? 
AOPP ????Witko-Sarsat ???? 66)????????20 μM ? normal-HSA ?? CT-HSA 
400 μL ? 1.16 M ??????? 10 μL??? 20 μL? 25?C?????340 nm?????????
????0~100 μM?????? T ?? 400 μL ? 1.16 M ??????? 10 μL??? 20 μL ???
??????????????AOPP ???????? 
 
?.? ??????????? (ONOO-) ??? 
100 mM ??????????? (pH7.4)?0.3 mg/mL ?????25 μM ??????????25 μM 
HSA ???????????0.3 N NaOH ???????? 0.56 mM ONOO- ??? 3:1 ????
??37?C? 5?????????? 485 nm????? 535 nm ???????????  
 
??? SDS-PAGE 
? SDS-PAGE ??12.5% ????????????????????????????????????
?????? R-250 ??????????????????????????????? 
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? ????????? (????66,000)??????????? (????140,000)?????? (?
???232,000)?????? (????440,000)????????? (????669,000)? 
 
??? ?????????? HSA???????? 
? Trp ???????????????????????????????????????????
HITACHI ? F-2500 ?????????????????? 295 nm ?????300?400 nm ?
???????????HSA ??? 2 μM (67 mM ??????) ????????? 
 
??? ??????? HSA ??????? 
7-1?ICG ????? 








? ????????? ICG ??HSA ? 2.5 μg/g ??????????????????????
????????????????????? 1 mL ??????6000 rpm? 5????????
?? 100 μL ?????????????? (Ex.774 nm?Em.805 nm) ???????ICG ??
HSA ?? 3 ??30 ??1 ???2???4??????????????????????? 2?
????? (?????????????) ????????????????????????? 








??? ??? ?? ????????????????? 
 
????????????????????????????????? ???  ??? ? ??
???? ?? ?? ????? ??? ??? ??????? ??? ?? ???????????
????? 
 
?????????????????????????????????? ??? ??? ??
???? ??? ?? ??????????????? 
 
??????????????????????????????? ????? ??? ? ???
?? ??? ??? ?????? ??? ??? ??????? ??? ?? ????????????? 
???? ??? ??? ?????????????? 
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